

DBV Technologies

Corporate Fact Sheet




CORPORATE OVERVIEW

DBV Technologies (DBV) is a clinical-stage biopharmaceutical company focused on discovering safe and effective treatments for patients with food allergies and other unmet medical needs.

DBV has developed a proprietary technology platform called Viaskin[®], which is based on epicutaneous immunotherapy, or EPIT[®], DBV's method of delivering biologically active compounds to the immune system. This novel mechanism of action accesses the immune system through intact skin without allowing passage of the antigen into the bloodstream. The company is also exploring Viaskin[®] in other areas of unmet need including vaccines, inflammatory conditions and autoimmune diseases.

DBV was founded in 2002 by Dr. Pierre-Henri Benhamou, Chairman and CEO, Dr. Christophe Dupont, Chairman of DBV's Scientific Advisory Board, and Mr. Bertrand Dupont, Chief Technology Officer.

DEVELOPMENT PIPELINE



*US FDA Breakthrough Therapy and Fast Track designation in children
**US FDA Fast Track designation in pediatric patients two and older

COMPANY HIGHLIGHTS

- Pioneer in first class of potential immunotherapy treatments
- Leader in treatments for food allergies and other unmet medical needs
- Creator of Viaskin[®], proprietary technology platform, and EPIT[®], novel mechanism of action for food allergies and other potential applications
- Leveraging innovative technology platform, pipeline of food allergy product candidates being developed that could potentially transform care of food-allergic patients
- Pipeline comprises two late-stage product candidates, Viaskin[®] Peanut and Viaskin[®] Milk, and one pre-clinical program, Viaskin[®] Egg
- Science collaboration with Nestlé Health underway for milk allergy diagnostic tool
- Experienced management team and highly collaborative and dedicated company culture

THE VIASKIN[®] PLATFORM

Pioneering a New Class of Immunotherapy through a Technology Platform, Viaskin[®]



We are developing Viaskin[®], a novel technology platform that potentially has broad applications in immunotherapy. Viaskin[®] is based on epicutaneous immunotherapy or EPIT[®], which aims to deliver biologically active compounds to the immune system through intact skin.

Our potential treatment paradigm is unique: Viaskin[®] is an electrostatic patch in development that activates the immune system through the skin, which may offer easy-to-use, self-administered and non-invasive treatments to patients.

LOCATIONS

HEADQUARTERS
Montrouge, France
New York, NY

NORTH AMERICA OPERATIONS
Summit, NJ

QUICK FACTS

TECHNOLOGY PLATFORM	MECHANISM OF ACTION	DBVT NASDAQ	DBV EURNXT
Viaskin [®]	EPIT [®]	Ticker	Ticker